FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q1 2026

SEC EDGAR SourceSEC Filings

Top Holdings173 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

ELECTRONIC ARTS INC

7.5M$1.5B8.0%$203.33-1.04%
2 qtrssince 2025-Q4
Increased
85
2.3M$1.5B7.8%
New

REVOLUTION MEDICINES INC

13.6M$1.3B6.9%$35.04+186.80%
21 qtrssince 2021-Q1
Decreased
0

AMAZON.COM INC

4.2M$878.6M4.6%$225.22-7.32%
4 qtrssince 2025-Q2
Decreased
0

MICROSOFT CORP

2.3M$868M4.6%$345.04+17.07%
30 qtrssince 2018-Q4
Increased
62

AON PLC

2.5M$811M4.3%$329.96-2.43%
9 qtrssince 2024-Q1
Decreased
0

BRIDGEBIO PHARMA INC

9.4M$695.5M3.6%$38.59+67.22%
7 qtrssince 2024-Q3
Increased
60
3.6M$690.9M3.6%
New

PROTAGONIST THERAPEUTICS INC

6.3M$669.2M3.5%$21.66+321.53%
30 qtrssince 2018-Q4
Increased
60

NATERA INC

3.2M$641.4M3.4%$74.46+178.07%
20 qtrssince 2021-Q2
Decreased
0

EXELIXIS INC

13.1M$562.3M2.9%$22.96+77.46%
30 qtrssince 2018-Q4
Decreased
0

BROADCOM INC

1.8M$550.8M2.9%$331.90-5.44%
2 qtrssince 2025-Q4
Increased
87

UNITEDHEALTH GROUP INC

1.8M$492.9M2.6%$422.06-31.48%
13 qtrssince 2023-Q1
Increased
61

SYNOPSYS INC

1.2M$481M2.5%$465.64-8.87%
2 qtrssince 2025-Q4
Increased
64

BOSTON SCIENTIFIC CORP

7.5M$468.8M2.5%$73.83+0.03%
23 qtrssince 2020-Q3
Increased
54

THERMO FISHER SCIENTIFIC INC

881,485$433.3M2.3%$468.41+8.47%
26 qtrssince 2019-Q4
Increased
71

KKR & CO INC

4.7M$432.1M2.3%

LANTHEUS HOLDINGS INC

5.6M$423.5M2.2%$78.29+0.70%
13 qtrssince 2023-Q1
Increased
55

WABTEC CORP

1.6M$402.2M2.1%$144.82+80.11%
30 qtrssince 2018-Q4
Decreased
0

SCHWAB (CHARLES) CORP

4M$371.8M1.9%$77.32+43.67%
6 qtrssince 2024-Q4
Increased
58
$19.1B
AUM
173
Positions
Q1 2026
Filing
Rating · 1.0
Quarterly Portfolio Change
-0%Q4'24$22.8B-9%Q1'25$20.9B+14%Q2'25$23.8B+3%Q3'25$24.4B-5%Q4'25$23.1B-17%Q1'26$19.1B
Activity profile
$ moved · Q1'26
New19%Increased19%Decreased15%Exited48%
Composition
Equity vs derivatives
Equity88%Puts11%Calls0%
Holding period
Avg 2.3 years
<1Q25%1-4Q16%1-2Y12%2Y+47%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $19.1B across 173 positions as of Q1 2026. Top holdings: EA (8.0%), STATE STREET SPDR S&P 500 ETF (7.8%), RVMD (6.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1/5.0.

Q1 2026 Summary

Active quarter - 48 new positions, 26 exits, 30 increased. Top move: AVGO (INCREASED, conviction 87). Portfolio: $19.1B across 173 positions.

Top holdings by portfolio weight

Total AUM$17B
EA7.99%
RVMD6.94%
AMZN4.61%
MSFT4.55%
AON4.25%
BBIO3.65%
PTGX3.51%
NTRA3.36%
EXEL2.95%
AVGO2.89%
Other2.59%

Portfolio allocation by GICS sector

Sectors11
Healthcare52.84%
Communication Services12.85%
Financial Services12.73%
Technology11.66%
Consumer Cyclical5.33%
Industrials4.11%
Real Estate0.24%
Unknown0.19%
Basic Materials0.03%
Energy0.01%
Other0.00%

Behavioral investing profile

7-dimension quality assessment
Weak(1.0 / 5.0)
Track RecordNo data
Conviction43
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q3 2024 Q2 2026+8.5M shares+$314.1M
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 Q2 2026+9M shares+$755.7M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used